SNSS - dowgraded today by webush but there's the skinny on it:
From 8/27 13:16 EDT - Sunesis (SNSS) is expected to soon announce late-stage study data for its blood-cancer drug, and UBS predicts results will be positive as it contends investors have been "overly cautious" going in to the disclosure. If the study is a home run, SNSS could spike to $25 and even higher afterwards on M&A speculation, the investment bank posits. It adds that in a best-case scenario, the drug could peak at $1.5B of annual sales. But if the study shows the drug works without a huge benefit, peak sales are more like to be $400M. A study failure, meanwhile, could have the stock crash to "near-current cash levels" of 60c/share. SNSS is up 6% at $7.94, hitting a fresh 4 1/2-year high. (joseph.walker@wsj.com)
Worth a lotto try?
